Syros Pharmaceuticals, Inc. (SYRS) Financials

SYRS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 168.2 million 151.5 million
2023-09-30 147.8 million 111.5 million
2023-06-30 181.0 million 107.7 million
2023-03-31 205.3 million 98.6 million

SYRS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -18.6 million 1.7 million
2023-09-30 -31.9 million 3.3 million
2023-06-30 -22.4 million 2.8 million
2023-03-31 -37.1 million 2.6 million

SYRS Net Income

No data available :(

SYRS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 139.5 million - 20.9 million
2023-09-30 112.2 million - 21.4 million
2023-06-30 144.0 million - 21.9 million
2023-03-31 165.8 million 39.1 million 22.4 million

SYRS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 29.5 million
2023-09-30 28.0 million
2023-06-30 27.9 million
2023-03-31 27.8 million

SYRS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 38000 21.2 million 5.9 million -
2023-09-30 - 28.3 million 7.8 million -
2023-06-30 1000 29.6 million 7.2 million -
2023-03-31 235000 28.8 million 7.4 million -

SYRS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 386000 279000
2023-09-30 3.8 million 616000
2023-06-30 2.8 million 653000
2023-03-31 3.0 million 704000

SYRS

Price: $5

52 week price:
2.09
8.17

Earnings Per Share: 0.85 USD

P/E Ratio: 8.42

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 234220

Ebitda: -13.6 million

Market Capitalization: 137.1 million

Links: